
- Volume 0 0
"The Pill" Is Linked with Diabetic Nephropathy
Researchers have found a new risk factorfor diabetic nephropathy—oral contraceptives(OCs). A strong association between therenin angiotensin system (RAS) and diabeticnephropathy led the researchers to explore apossible link with OC use. Initially the studyincluded 12 patients with diabetes who usedOCs and 10 patients without diabetes whoused oral OCs. The study also included 29patients with diabetes and 41 patients withoutthe disease, all of whom did not use OCs.Renal plasma flow (RPF) in response to captoprilwas used as an index of RAS activity.
The results of the study, reported in DiabetesCare (August 2005), showed thatpatients without diabetes who did not use OCshad a "minimal" increase in RPF, comparedwith a greater increase in patients without thedisease who used birth control. Furthermore,patients with diabetes who did not use OCshad a dramatically greater than anticipatedincrease. The vasodilator response, however,was most prevalent in the diabetic OC group.
The researchers went a step further tomeasure the impact of OC use in 114 womennewly diagnosed with type 1 diabetes. After 20years of follow-up, 18% of the OC groupdeveloped macroalbuminuria, compared with2% of nonusers of OCs. When the researchersadjusted for age at onset and bloodpressure, OC use remained a major predictorof development of the nephropathy.
Articles in this issue
about 20 years ago
A Pharmacist's Guide to OTC Therapy: Ocular Care Productsabout 20 years ago
Dangerous Liaisons: Schizophrenia and Diabetesabout 20 years ago
A Pharmacist's Guide to OTC Therapy: Diabetic Nutritional Supplementsabout 20 years ago
Tarceva Extends Lung Cancer Survivalabout 20 years ago
Inhaled Morphine Aids Cancer-related Dyspneaabout 20 years ago
Diuretic Best BP Therapy for African Americansabout 20 years ago
A Pharmacist's Guide to OTC Therapy: Diabetic Foot Care Productsabout 20 years ago
New Drug Blocks Out AIDS Virusabout 20 years ago
Viagra Ingredient Has Another Useabout 20 years ago
GUEST COMMENTARY: FIGHTING THE NEW PHARMACOPHOBIANewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

















































































































































































































